hh2853
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2020 (NCT04390737)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EZH1 inhibitor
EZH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06909877 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2022 | ShangHai HaiHe Pharmaceutical, University of Electronic Science and Technology of China |
| NCT04390737 | Phase 1 | May 23, 2020 | Mayo Clinic, ShangHai HaiHe Pharmaceutical |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ShangHai HaiHe Pharmaceutical | For profit | 2 | 2 | 2 | 2020 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Electronic Science and Technology of China | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1